The STARS-Trial: To Assess Stent Apposition by Optical Coherence Tomography (OCT) of the Svelte Sirolimus-Eluting Coronary Stent Systems (IDS and RX) Compared to the Abbott Vascular Xience Everolimus-Eluting Coronary Stent System for the Treatment of Atherosclerotic Lesions in a Randomized Study

The STARS-Trial: To Assess Stent Apposition by Optical Coherence Tomography (OCT) of the Svelte Sirolimus-Eluting Coronary Stent Systems (IDS and RX) Compared to the Abbott Vascular Xience Everolimus-Eluting Coronary Stent System for the Treatment of Atherosclerotic Lesions in a Randomized Study - STARS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON55040

Enrollment

250

Registered

2020-04-23

Start date

2020-10-06

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Svelte Sirolimus-eluting stents vs. Abbott Vascular Xience Everolimus-eluting stent

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia

Exclusion criteria

Exclusion criteria: - Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmia, or ongoing intractable angina;

Design outcomes

Primary

Measure	Time frame
Stent appossition	—

Secondary

Measure	Time frame
Stent expansion Edge dissection Total number of balloons used	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)